Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor

Trial Profile

Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Pegargiminase (Primary) ; Doxorubicin
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Apr 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 24 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top